| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (Merck) MK-7902-001 / E7080-G000-313 / LEAP-001 | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma | Hirte, Dr Hal | Open to recruitment | NCT03884101 |
| (Roche) WO42017 / SKYSCRAPER 04 | A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1−POSITIVE CERVICAL CANCER | Hirte, Dr Hal | Open to recruitment | NCT04300647 |
| (Tesaro) 3000-03-005 / ENGOT-OV44 / FIRST | A Patient Centric Randomized Phase 3 Comparison of Standard of Care Platinum Based Therapy to the Same Plus TSR-042 As First Line Treatment of Patients with Stage III or IV Non-Mucinous Ovarian Cancer. | Hirte, Dr Hal | Open to recruitment | NCT03602859 |
| (UHN) BioDIVA | Biomarker Discovery Project in High Grade Serous Ovarian Cancer | Reade, Dr Clare | Recruitment on hold - COVID-19 | NCT03419689 |
Find a Trial
Contact Us